Medical University of South Carolina 47th Cardiology Update 2025

MUSC Cardiology Update 2025: 47th Annual Conference

Medical University of South Carolina 47th Cardiology Update 2025 is a comprehensive clinical cardiology program focused on evidence-based diagnostic and treatment strategies for cardiovascular disease, including cardiac arrhythmias, heart failure, preventive cardiology, structural heart disease, coronary interventions, cardiomyopathies, cardiac imaging, and emerging cardiovascular therapies.

+ Target Audience

Cardiologists, Clinical Cardiac Electrophysiologists, Interventional Cardiologists, Heart Failure Specialists, Preventive Cardiologists, Primary Care Physicians, Internists, Cardiovascular Nurses, Physician Assistants, and other healthcare professionals involved in cardiovascular care.

The program is particularly relevant for:

• General Cardiologists
• Clinical Cardiac Electrophysiologists
• Interventional Cardiologists
• Heart Failure Specialists
• Preventive Cardiologists
• Cardiovascular Imaging Specialists
• Cardiovascular Radiologists
• Primary Care Physicians
• Internists
• Endocrinologists
• Neurologists
• Sleep Medicine Specialists
• Hepatologists
• Cardiovascular Nurses
• Physician Assistants
• Advanced Practice Providers
• Cardiology Fellows and Trainees

+ Information

The management of patients with cardiovascular disease continues to evolve as new evidence, technologies, medications, imaging strategies, and catheter-based interventions become integrated into clinical practice.

The goal of the Medical University of South Carolina 47th Cardiology Update 2025 is to provide clinicians with current, evidence-based diagnostic and treatment strategies for patients with cardiovascular disease.

The three-day program addresses core and emerging areas of clinical cardiology, including:

• Cardiac arrhythmias
• Atrial fibrillation
• Stroke prevention
• Ventricular arrhythmias
• Cardiac implantable electronic devices
• Heart failure
• Cardiomyopathies
• Preventive cardiology
• Hypertension
• Cardiometabolic disease
• Structural heart interventions
• Coronary interventions
• Cardiovascular imaging
• Pulmonary embolism
• Cardiac genetics
• Emerging cardiovascular therapies

The educational format emphasizes practical clinical decision-making through case-based presentations, lectures, breakfast cases, panel discussions, and interactive audience-response sessions.

Course Details

• Course: 47th Cardiology Update – Evidence-Based Management
• Institution: Medical University of South Carolina (MUSC)
• Year: 2025
• Dates: May 29–31, 2025
• Duration: 3 Days
• Location: Charleston, South Carolina
• Venue: Hyatt Place Hotel
• Specialty: Clinical Cardiology
• Educational Focus: Evidence-Based Cardiovascular Management

Program Overview

The 47th Cardiology Update provides a clinically oriented review of contemporary cardiovascular medicine.

Rather than focusing exclusively on individual diseases, the program integrates diagnosis, risk stratification, medical therapy, imaging, procedural management, and multidisciplinary decision-making across a broad range of cardiovascular disorders.

Particular attention is given to rapidly evolving areas such as:

• Atrial fibrillation management
• Ventricular arrhythmias
• Cardiovascular implantable electronic devices
• Heart failure with preserved ejection fraction
• Cardiometabolic disease
• GLP-1 receptor agonists
• Lipoprotein(a)
• Cardiac amyloidosis
• Myocarditis
• Artificial intelligence in cardiovascular care
• Structural heart interventions
• Contemporary coronary intervention
• Renal denervation

Learning Objectives

At the conclusion of this activity, participants should be able to:

• Formulate evidence-based diagnostic, risk-stratification, and treatment algorithms for complex cardiac rhythm disorders, including atrial fibrillation, stroke prophylaxis, and ventricular arrhythmias.
• Evaluate malfunctions and complications related to cardiac implantable electronic devices (pacemakers and defibrillators) and execute appropriate troubleshooting protocols.
• Apply guideline-directed medical therapy (GDMT) and emerging pharmaceutical options (including GLP-1 receptor agonists and novel lipid-lowering therapies for Lp(a)) across heart failure phenotypes, notably HFpEF and cardiometabolic diseases.
• Recognize, evaluate, and manage non-ischemic and infiltrative cardiomyopathies, including cardiac amyloidosis and fulminant myocarditis.
• Integrate multimodality preventive imaging, cardiac genetics, and artificial intelligence tools to optimize cardiovascular risk assessment and heart failure care pathways.
• Analyze indications, procedural strategies, and patient outcomes for contemporary catheter-based structural and coronary interventions, including TAVR, transcatheter tricuspid interventions, patent foramen ovale (PFO) closure, in-stent restenosis management, and renal denervation.

Major Topics

Cardiac Electrophysiology and Arrhythmias

• Atrial Fibrillation
• AF Risk Stratification
• Rhythm Control
• Rate Control
• Stroke Prevention in Atrial Fibrillation
• Anticoagulation
• Ventricular Arrhythmias
• Ventricular Tachycardia
• Arrhythmia Risk Assessment
• Contemporary Electrophysiology Management
• Complex Rhythm Disorders

Cardiac Implantable Electronic Devices

• Pacemakers
• Implantable Cardioverter-Defibrillators
• Cardiac Implantable Electronic Devices
• Device Malfunction
• Device-Related Complications
• Pacemaker Troubleshooting
• ICD Troubleshooting
• Device Interrogation
• Clinical Management of Device Problems

Heart Failure

• Guideline-Directed Medical Therapy
• Heart Failure with Reduced Ejection Fraction
• Heart Failure with Preserved Ejection Fraction
• HFpEF
• Cardiometabolic Heart Failure
• Contemporary Heart Failure Pharmacotherapy
• Multidisciplinary Heart Failure Management
• Advanced Heart Failure
• Heart Failure Risk Assessment
• Emerging Heart Failure Therapies

Cardiometabolic Disease

• Cardiovascular Disease and Obesity
• GLP-1 Receptor Agonists
• Cardiometabolic Risk Reduction
• Diabetes and Cardiovascular Disease
• Obesity Management
• Heart Failure and Metabolic Disease
• Cardiovascular Prevention

Preventive Cardiology

• Cardiovascular Risk Assessment
• Lipid Management
• Lipoprotein(a)
• Novel Lipid-Lowering Therapies
• Hypertension
• Primary Prevention
• Secondary Prevention
• Cardiovascular Risk Modification
• Preventive Imaging
• Cardiovascular Genetics

Cardiomyopathies

• Non-Ischemic Cardiomyopathy
• Infiltrative Cardiomyopathy
• Cardiac Amyloidosis
• Myocarditis
• Fulminant Myocarditis
• Cardiomyopathy Diagnosis
• Genetic Cardiomyopathy
• Multimodality Imaging
• Contemporary Cardiomyopathy Management

Cardiovascular Imaging

• Echocardiography
• Cardiac CT
• Cardiac MRI
• Multimodality Cardiovascular Imaging
• Preventive Cardiovascular Imaging
• Structural Heart Imaging
• Imaging in Cardiomyopathy
• Imaging for Cardiovascular Risk Assessment

Artificial Intelligence in Cardiology

• Artificial Intelligence in Cardiovascular Medicine
• AI-Based Risk Assessment
• AI in Cardiovascular Imaging
• Artificial Intelligence in Heart Failure
• Clinical Decision Support
• Emerging Digital Cardiovascular Technologies

Structural Heart Disease

• Transcatheter Aortic Valve Replacement
• TAVR
• Aortic Valve Disease
• Transcatheter Tricuspid Intervention
• Tricuspid Valve Disease
• Patent Foramen Ovale
• PFO Closure
• Structural Heart Patient Selection
• Catheter-Based Structural Intervention
• Procedural Outcomes

Interventional Cardiology

• Contemporary Coronary Intervention
• Percutaneous Coronary Intervention
• Coronary Artery Disease
• In-Stent Restenosis
• Management of Complex Coronary Disease
• Catheter-Based Therapies
• Procedural Strategy
• Interventional Outcomes

Hypertension

• Contemporary Hypertension Management
• Resistant Hypertension
• Cardiovascular Risk Reduction
• Renal Denervation
• Patient Selection for Renal Denervation
• Guideline-Based Blood Pressure Management

Pulmonary Embolism and Cardiopulmonary Disease

• Pulmonary Embolism
• Cardiovascular Consequences of Pulmonary Embolism
• Risk Stratification
• Diagnostic Evaluation
• Medical Management
• Multidisciplinary Cardiovascular Care

Emerging Cardiovascular Therapies

• Novel Heart Failure Medications
• GLP-1 Receptor Agonists
• Novel Lipid-Lowering Therapies
• Lp(a)-Directed Treatment
• Renal Denervation
• Transcatheter Valve Therapies
• Contemporary Electrophysiology Strategies
• Artificial Intelligence in Cardiology
• Precision Cardiovascular Medicine

Course Directors

Michael R. Gold, MD, PhD

Course Director

Michael Assey Professor of Medicine
Division of Cardiology
Medical University of South Carolina

Christopher D. Nielsen, MD

Assistant Course Director

Director, Adult Cardiac Labs
Director, Interventional Fellowship Program
Professor of Cardiology

Selected Faculty

The official MUSC program includes cardiovascular specialists from MUSC and visiting faculty, including:

• Daniel Silverman, MD
• Nicholas Amoroso, MD
• Gregory Jackson, MD
• Jan Basile, MD
• Daniel Steinberg, MD
• Daniel P. Judge, MD, FACC, FHFSA

Faculty expertise represented areas including general cardiology, advanced heart failure, structural heart disease, cardiovascular prevention, and other subspecialty areas of cardiovascular medicine.

Target Audience

This three-day program in clinical cardiology is designed for:

• Cardiologists
• Primary Care Physicians
• Internists
• Practicing Cardiovascular Specialists
• Cardiovascular Nurses
• Physician Assistants

Best For

The program is especially relevant for:

• Cardiologists
• Clinical Cardiac Electrophysiologists
• Interventional Cardiologists
• Heart Failure Specialists
• Preventive Cardiologists
• Cardiovascular Radiologists
• Cardiovascular Imaging Specialists
• Endocrinologists
• Hepatologists
• Sleep Medicine Specialists
• Neurologists
• Primary Care Physicians
• Internal Medicine Physicians
• Cardiovascular Advanced Practice Providers

Why This Course Is Relevant

Clinical cardiology is changing rapidly as new medications, devices, imaging modalities, catheter-based interventions, and digital technologies reshape cardiovascular diagnosis and treatment.

The Medical University of South Carolina 47th Cardiology Update 2025 brings these developments together in a clinically focused program designed to support evidence-based patient care.

The program is particularly valuable for clinicians seeking updates in atrial fibrillation, heart failure, HFpEF, cardiovascular prevention, cardiac amyloidosis, structural heart disease, TAVR, interventional cardiology, cardiovascular imaging, GLP-1 therapy, Lipoprotein(a), renal denervation, and artificial intelligence in cardiology.

Its case-based format also helps translate emerging cardiovascular evidence into practical diagnostic and therapeutic decisions.

Short Description

Medical University of South Carolina 47th Cardiology Update 2025 provides evidence-based updates in clinical cardiology, including atrial fibrillation, cardiac devices, heart failure, HFpEF, GLP-1 therapies, Lp(a), cardiomyopathies, cardiac amyloidosis, cardiovascular imaging, TAVR, structural heart interventions, coronary disease, renal denervation, and emerging cardiovascular technologies.

Topics

• The First Pillar of AF Management – Risk Factor Modification with Focus on Obesity

• Ventricular Arrhythmia Identification & Management

• Optimizing Stroke Prophylaxis in Atrial Fibrillation Management

• Cardiac Implantable Devices Gone Wrong – Diagnosis and Management of Malfunctioning Pacemakers and Defibrillators

• Atrial Fibrillation in 2025 – Pearls for the non-EP

• Update on Novel Therapies for Treating Elevated Lp(a)

• HFpEF Is a Metabolic Disease – Evidence and Implications

• Approach to Liver Disease in the Patient with Cardiometabolic Risk

• Changing the Paradigm – The Top Recent Trials in Preventive Cardiology and Cardiometabolic Health

• Update in Preventive Imaging

• Best Cases of the Year – Dyspnea & Fulminant Myocarditis Cases

• The Future Is Here – Artificial Intelligence and Imaging in Heart Failure

• Transforming Heart Failure into Heart Success – Heart Failure Transitions of Care

• Cardiac Genetics and Genomics

• Don’t Sleep on It – Heart Failure and Sleep Disordered Breathing

• Reaching a New Peak – Results of SUMMIT and GLP-1 Agonists in HFpEF

• Emerging Treatment Strategies and Clinical Trials for Cardiac Amyloidosis

• Pharmacy Integration into Multidisciplinary Heart Failure Clinics – Optimizing GDMT Despite Real-World Barriers

• No Longer Limited Options – New and Emerging Treatments for HFpEF

• Coronary Artery Disease Chest Pain Case Studies Discussion

• Patent Foramen Ovale Closure – Secondary Stroke Prevention and More

• Treatment of In-Stent Restenosis

• Renal Denervation for Treatment of Hypertension

• TBA Topic

• New Treatments for Tricuspid Valve Disease

• Update in TAVR (and Other Valves)